|Bid||66.77 x 1000|
|Ask||66.78 x 1200|
|Day's range||66.36 - 66.96|
|52-week range||53.52 - 76.56|
|Beta (5Y monthly)||0.17|
|PE ratio (TTM)||33.64|
|Forward dividend & yield||1.45 (2.14%)|
|Ex-dividend date||10 Aug 2023|
|1y target est||83.71|
AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Fasenra and Farxiga should keep driving revenues. Its pipeline is strong, with several phase III data readouts lined up.
Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.
In the latest trading session, Astrazeneca (AZN) closed at $67.42, marking a -0.77% move from the previous day.